



November 11, 2011

Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2011

Company Name: SymBio Pharmaceuticals Limited

(URL <http://www.symbiopharma.com/>)

Security Code: 4582

TEL: +81-3-5472-1125

President/ Representative Director and Chief Executive Officer: Fuminori Yoshida

Inquiries/ Board Director and Chief Financial Officer: Hiroki Maekawa

(Millions of Yen - rounded down unless otherwise stated)

1. Financial Results for the Third Quarter of Fiscal Year 2011 (January 1 to September 30)

(1) Financial Results (Cumulative)

	Net Sales		Operating Income		Ordinary Income		Quarterly Net Income	
	%		%		%		%	
3 rd Quarter FY 2011	1,306	—	(1,757)	—	(1,766)	—	(1,775)	—
3 rd Quarter FY 2010	—	—	—	—	—	—	—	—

	Quarterly Net Income per Share(Yen)	Diluted Quarterly Net Income per Share(Yen)
3 rd Quarter FY 2011	(131.65)	—
3 rd Quarter FY 2010	—	—

Note:

- Despite the issuance of new share subscription rights, information in connection with diluted quarterly net income per share will not be disclosed due to quarterly net loss per share.
- As quarterly disclosure of financial results began 1st quarter FY 2011, prior financial information is not included in the above chart.

(2) Financial Position

	Total Assets	Net Assets	Equity Ratio (%)	Shareholders' Equity per Share(Yen)
3 rd Quarter FY 2011	4,733	4,307	91.0	307.01
FY 2010	4,262	4,083	95.8	36,541.74

Note:

- Shareholders' equity 3Q FY 2011: 4,307 Million Yen, FY 2010: 4,083 Million Yen
- The Company carried out a stock split (100:1) on June 2nd, 2011

2. Dividends

(Date of Record)	Dividend Per Share (Yen)				
	1st Quarter	2nd Quarter	3rd Quarter	Fiscal Year End	Full Year
FY 2010	—	0.00	—	0.00	0.00
FY 2011	—	0.00	—		
FY 2011 (Forecast)				0.00	0.00

Note:

- Revision of forecast for dividends in this quarter: No

3. Forecast of Financial Results for Fiscal Year 2011 (January 1 to December 31)

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share (Yen)
	%	%	%	%	
Full Year	1,933 33.4	(2,351) —	(2,398) —	(2,407) —	(164.39)

Note:

1. Revision of this quarterly forecast in this quarter: No
2. Figures calculated above include the increase in shares from initial public offering in FY 2011

4. Other Information

Note: For further details, please refer to “2. Other Information” in attachments.

(1) Simplified accounting treatment: Not applied

(2) Changes in accounting rules, procedures and representation method in relation to the preparation of quarterly financial statements:

1. Changes in accounting principles: Yes
2. Changes other than (1): No

(3) Number of issued shares (common shares):

1. Number of issued shares at the end of period (including treasury shares)
Third quarter of FY 2011: 14,030,900 shares, FY 2010: 111,737 shares
2. Number of treasury shares at the end of period
Third quarter of FY 2011: - shares, FY 2010: - shares
3. Average number of shares during this period (quarterly cumulative period)
Third quarter of FY 2011: 13,483,900 shares, Third quarter in FY 2010: - shares

Note: The Company carried out a stock split (100:1) on June 2nd, 2011

Quarterly Review Procedures

This quarterly business report is out of scope for the quarterly review procedure based on Financial Instruments and Exchange Act. On the other hand, review procedure for quarterly financial statements has already been completed at the timing of this disclosure.

Information regarding proper use of financial forecasts, and other important matters

The aforementioned forecasts are estimates made by the Company based on information available at the time, and are subject to risks and uncertainties. Actual results may differ substantially from such forecasts due to various factors. Please refer to “Forecast of Business Results for Fiscal Year 2011” in Attachments.

[Attachments]

1. Financial Results Analysis, Financial Statements

As the Company has started reporting quarterly financial results from the First Quarter of FY 2011, this report does not include financial comparison analysis with the First Quarter of FY 2010. Regarding descriptions of future events and forecasts, the company made the decision to disclose such information at the time of release of this report

(1) Financial Results Analysis

Financial status of the Company until the end of the Third Quarter of FY 2011 is as follows:

1. Japan

In Japan, the Company's lead oncology drug SyB L-0501 (generic name: bendamustine hydrochloride, product name TREAKISYM®) was launched by the Company's business partner, Eisai Co., Ltd. (Eisai), on December 10, 2010 with the approved indications of refractory and relapsed low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Since its launch in Japan, TREAKISYM® sales remain steady.

The Company is capitalizing on this "pipeline within a molecule" as it pursues additional indications having a larger patient population. In Japan and South Korea, the joint phase 2 clinical trial of SyB L-0501 for refractory and relapsed intermediate/high-grade NHL is ongoing with patient registration completed in June, 2011.

In addition, preparations for two phase 2 clinical trials of SyB L-0501, one for the treatment of patients with refractory and relapsed multiple myeloma and the other for the treatment of frontline low-grade NHL and MCL, are underway.

The phase 2 clinical trial of the Company's second drug candidate, SyB D-0701 (transdermal antiemetic patch containing granisetron) for the treatment of radiotherapy-induced nausea and vomiting, is ongoing.

A third oncology drug candidate, SyB 0702 (polyethylene glycol-conjugated zinc protoporphyrin) and Hsp32 inhibitor, is currently undergoing preclinical studies to support the initiation of a phase 1 clinical trial.

The Company signed a License Agreement with Onconova Therapeutics, Inc., a private biopharmaceutical company located in Newtown, PA and Princeton NJ, USA, on July 7, 2011, to acquire exclusive development and marketing rights in Japan and South Korea for the oncology drug SyB L-1101 (iv formulation)/ SyB C-1101 (oral formulation) (generic name: rigosertib). Preparations for the phase I clinical trial to treat Japanese patients with refractory and relapsed MDS are ongoing.

2. Overseas

In Singapore, SyB L-0501 continues to show healthy growth in sales. In South Korea, the drug was launched in October, 2011, through Eisai after receiving marketing approval from the Korea and Food Drug Administration for frontline chronic lymphocytic leukemia and multiple myeloma.

In Taiwan, the Company's business partner, InnoPharmax Inc., received marketing approval from the Taiwan Food and Drug Administration for SyB L-0501 on October 18, 2011, for the treatment of refractory and relapsed low-grade NHL and frontline CLL with preparations underway for launch.

3. Financial Results

As a result of these activities, total quarterly sales revenue was 324,243 thousand yen due to TREAKISYM® sales. Sales and general administrative costs totaled 1,135,920 thousand yen. The Company posted R&D expenditures totaling 937,600 thousand yen mainly comprising costs of clinical development. R&D expenditures included included preparations for all indications of SyB L-0501, clinical trial costs of SyB D-0701, pre-clinical costs of SyB 0702, and upfront payment for the recently in-licensed drug candidate, SyB L-1101 / SyB C-1101. Other sales and general administrative costs amounted to 198,320 thousand yen.

Thus, for the Third Quarter, the operating loss was 1,056,425 thousand yen. The foreign exchange gain and other non-operating revenues totaled 12,397 thousand yen. However, non-operating expenses due to IPO-related costs and other expenses totaled 22,830 thousand yen, leading to an ordinary loss of 1,066,858 thousand yen. Net loss after tax was recorded as 1,067,808 thousand yen.

(2) Financial Position Analysis

1. Financial Position

Total assets as of September 30, 2011, stood at 4,733,674 thousand yen, an increase of 470,890 thousand yen compared to the previous financial year end. Current assets stood at 4,680,997 thousand yen, an increase of 468,197 thousand yen compared to the previous financial year end; this is the result of new shares being issued through third-party allocation, thereby increasing cash and cash deposits as well as TREAKISYM® sales, thereby increasing accounts payable and inventories. Fixed assets increased by 2,693 thousand yen up to 52,676 thousand yen.

Total liabilities stood at 426,104 thousand yen, with an increase of 246,385 thousand yen compared to the previous financial year end. Current liabilities totaled 424,106 thousand yen, an increase of 246,222 thousand yen compared to the previous financial year end, mainly due to an increase in accounts payable arising from an increase in sales of TREAKISYM® as well as other accounts payable. Fixed liabilities at the end of this Third Quarter were posted as 1,998 thousand yen, solely due to retirement benefit reserves.

Net assets increased to 4,307,569 thousand yen, up by 224,505 thousand yen compared to the previous financial year end. Despite net loss after tax totaling 1,775,148 thousand yen due to loss carried forward (negative profit surplus), new shares were issued through third-party allocation which resulted in an increase of 1,000,020 thousand yen in capital stock and capital reserves, increasing capital to 4,710,850 thousand yen and capital reserves to 4,680,850 thousand yen. Capital-to-asset ratio decreased to 91.0% by 4.8% compared to the previous financial year end.

2. Cash Flow

Cash and cash equivalents (cash) at the end of the Third Quarter of FY 2011 decreased to 4,073,668 thousand yen, a decrease of 1,244,222 thousand yen over the previous financial year end.

The following is a breakdown of the cash flow position and factors prevailing in the Third Quarter of FY 2011.

<Cash Flow from Operating Activities>

The cash flow from operating activities was recorded as a negative balance of 973,518 thousand yen. Despite inventories decreasing by 140,397 thousand yen and other accounts payable increasing by 13,476 thousand yen, a pre-tax net loss for the quarter of 1,066,858 thousand yen was posted, and accounts payable and other liabilities decreased by 54,144 thousand yen and 11,695 thousand yen, respectively.

<Cash Flow from Investment Activities>

Cash flow from investment activities ended with a negative balance of 3,328 thousand yen. This was mainly due to deposits and guarantees of 3,825 thousand yen.

<Cash Flow from Financing Activities>

Cash flow from financing activities was recorded as a negative balance of 250,000 thousand yen. This was due to 250,000 thousand yen in short-term loans borrowed for the payment of liabilities purchased for TREAKISYM®

(3) Forecast of Financial Results for Fiscal Year 2011

Progress in pipeline development will lead to greater R&D expenditures, resulting in a rise of sales and general administrative costs to 3,021 million yen, a significant increase on a year-on-year basis. The development plan for each pipeline product is outlined below.

<SyB L-0501>

The phase 2 clinical trial of SyB L-0501 for the treatment of patients with refractory and relapsed intermediate/high-grade NHL will continue. The first patient registration for phase 2 clinical trial in frontline NHL and MCL was completed on November 9, 2011 and further patient registration will continue.

Preparations will also continue for the development of the drug for refractory and relapsed multiple myeloma. To extend the life-cycle management of SyB L-0501, development of additional indications will be further explored.

<SyB 1101>

The Company will continue with preparations for the initiation of the phase 1 clinical trial for the treatment of patients with refractory and relapsed myelodysplastic syndrome (MDS).

<SyB D-0701>

The phase 2 clinical trial for radiotherapy-induced nausea and vomiting will continue.

<SyB 0702>

Based on the results of pre-clinical studies, the next stage of development activities will be considered further.

In terms of profit, TREAKISYM® is expected to continue to generate significant revenues, and the Company will continue to drive sales upward through its partnership with Eisai. Sales revenues from SyB L-0501 in Singapore, Korea, and Taiwan are expected to be booked before the end of 2011. The sales and marketing activities in these three markets are the responsibility of Eisai (Singapore) Pte. Ltd., Eisai Korea Inc., and InnoPharmax Inc., respectively.

Given this outlook, the forecast for the fiscal year ending on December 31, 2011, is as follows: sales of 1,933 million yen, operating loss of 2,351 million yen, ordinary loss of 2,398 million yen, and net loss of 2,407 million yen.

2. Other Information

(1) No simplified accounting or special accounting methods were used for the compilation of quarterly financial statements

(2) Changes have taken place in principles, procedures and presentation methods used in accounting for the compilation of quarterly financial statements

Application of accounting standards relating to asset retirement obligations:

Starting from the First Quarter of FY 2011, Accounting Standards Relating to Asset Retirement Obligations (Corporate Accounting Standards No. 18: March 31, 2008) and the Application Guideline for Accounting Standards Relating to Asset Retirement Obligations (Corporate Accounting Standards Application Guideline No. 21: March 31, 2008) have been applied.

This has resulted in an increase of 1,363 thousand yen in operating loss and ordinary loss for Third Quarter of FY 2011 (cumulative), and an increase of 6,694 thousand yen in pre-tax net loss and current net loss for the Third Quarter.

Furthermore, the application of this accounting standard has resulted in a decrease of 5,331 thousand yen in “deposits and guarantees” for investment and other assets.

(3) No significant event has occurred regarding the going concern of the Company.

3. Quarterly Financial Statements

(1) Quarterly Balance Sheet

(Unit: Thousands of Yen)

	As of September 30, 2011	As of December 31, 2010
Assets		
Current Assets		
Cash & Deposits	2,321,712	2,314,484
Accounts Receivable	179,319	5,934
Valuable Securities	1,851,975	1,701,323
Inventories	95,778	—
Prepaid Expenses	101,253	101,905
Advances	73,104	86,081
Other Current Assets	57,853	3,070
Total Current Assets	4,680,997	4,212,800
Fixed Assets		
Tangible Fixed Assets		
Building (Net)	2,509	2,631
Fixtures & Equipment (Net)	16,080	19,295
Total Tangible Fixed Assets	18,590	21,927
Intangible Fixed Assets		
Software	10,174	772
Total Intangible Fixed Assets	10,174	772
Investments & Other Assets		
Security Deposits	23,911	27,282
Total Investments & Other Assets	23,911	27,282
Total Fixed Assets	52,676	49,982
Total Assets	4,733,674	4,262,783

(Unit: Thousands of Yen)

	As of September 30, 2011	As of December 31, 2010
Liabilities		
Current Liabilities		
Accounts Payable	192,189	1,168
Accounts Payable -other	201,995	124,323
Income Tax Payable	7,638	10,702
Other Current Liabilities	22,284	41,690
Total Current Liabilities	424,106	177,884
Long-Term Liabilities		
Accrued Retirement Benefits	1,998	1,835
Total Long-Term Liabilities	1,998	1,835
Total Liabilities	426,104	179,719
Net Assets		
Shareholders' Equity		
Capital Stock	4,710,850	3,710,830
Capital Surplus	4,680,850	3,680,830
Earned Surplus	(5,083,726)	(3,308,577)
Total Shareholders' Equity	4,307,973	4,083,082
Appraisal and Conversion Variance, etc.		
Other Valuable Securities Appraisal Variance	(404)	(18)
Total Appraisal and Conversion Variance, etc.	(404)	(18)
Total Net Assets	4,307,569	4,083,064
Total Liabilities and Net Assets	4,733,674	4,262,783

(2) Quarterly Income Statement
(9 month to September 30, 2011)

(Unit: Thousands of Yen)

	Third Quarter Fiscal Year 2011 January 1, 2011 to September 30, 2011
Net Sales	1,306,894
Cost of Sales	891,549
Gross Profit	415,345
Selling, General and Administrative Expenses	2,173,104
Operating Loss	1,757,759
Total Non-Operating Income	55,514
Total Non-Operating Expense	64,723
Ordinary Loss	1,766,967
Total Extraordinary Expense	5,331
Net Loss before Tax	1,772,298
Income Tax Total	2,850
Net Loss	1,775,148

(3 month to September 30, 2011)

(Unit: Thousands of Yen)

	Third Quarter Fiscal Year 2011 July 1, 2011 to September 30, 2011
Net Sales	324,243
Cost of Sales	244,748
Gross Profit	79,494
Selling, General and Administrative Expenses	1,135,920
Operating Loss	1,056,425
Total Non-Operating Income	12,397
Total Non-Operating Expense	22,830
Ordinary Loss	1,066,858
Net Loss before Tax	1,066,858
Income Tax Total	950
Net Loss	1,067,808

(3) Quarterly Cash Flow Statements

	(Unit: Thousands of Yen)
	Third Quarter Fiscal Year 2011 January 1, 2011 to September 30, 2011
Cash Flow from Operating Activities	
Net Loss before Tax	(1,772,298)
Depreciation Expense	6,042
Other Depreciation Expenses	1,751
Loss on adjustment for changes of accounting standard for asset retirement obligations	5,331
Increase in Accrued Retirement Benefits	163
Interest Income	(2,557)
Interest Expense	664
Foreign Exchange Loss	20,428
New Share Issuing Expense	7,000
Commission paid	16,828
Increase in Accounts Receivable	(173,384)
Increase in Inventories	(95,778)
Increase in Prepaid Expense	(16,176)
Decrease in Advances	12,977
Increase in Other Current Assets	(62,889)
Increase in Account Payable	191,020
Increase in Account Payable –other	77,672
Decrease in Other Current Liabilities	(13,413)
Others	460
Subtotal	(1,796,158)
Interest and Dividends Received	2,748
Interest Expenses Paid	(664)
Income Tax Paid	(3,800)
Net Cash Used by Operating Activities	(1,797,874)

(Unit: Thousands of Yen)

Third Quarter Fiscal Year 2011 January 1, 2011 to September 30, 2011	
Cash Flow from Investing Activities	
Payment for Purchase of Securities	(100,610)
Securities Redemption Revenue	100,000
Payment for purchase of tangible fixed assets	(1,167)
Payment for purchase of intangible fixed assets	(10,940)
Payment for other investments	(4,257)
Proceeds from investments and other assets	546
Net Cash Used by Investing Activities	(16,428)
Cash Flow from Financing Activities	
Proceeds from Issuance of New Stock	2,000,040
Payment for Issuance of New Stock	(7,000)
Net Cash Provided by Financing Activities	1,993,039
Effect of Foreign Exchange Rate Changes on Cash and Cash Equivalents	(20,833)
Net Increase (Decrease) in Cash and Cash Equivalents	157,903
Cash and Cash Equivalents at the Beginning of the Period	3,915,765
Cash and Cash Equivalents at the End of the Period	4,073,668

(4) Business Continuity

Not applied.

(5) Segment Information

Segment information was not included as our business is a single business unit, namely drug research & development, manufacturing & sales, and other related activities.

(Additional Information)

Since this quarter, the Accounting Standards Relating to Segment Information Disclosure (Corporate Financial Reporting Standards No.17: March 27, 2009) and the Guideline for the Application of Accounting Standards Relating to Application of Accounting Standards for Segment Information Disclosure (Corporate Financial Reporting Standards Application Guideline No. 20: March 21, 2008) have been applied.

(6) Explanatory note concerning significant fluctuations in Shareholders' Equity

The resolution was passed at Board of Directors meeting held on February 14, 2011, with respect to third party allotment of 1,988,000 thousand yen (70,000 yen per stock), and the Company completed the process by February 25, 2011.

The resolution was passed at the Board of Directors meeting held on March 30, 2011, with respect to third party allotment of 12,040 thousand yen (70,000 yen per stock), and the Company completed the process by April 26, 2011. As a result, Capital Stock amounted to 4,710,850 thousand yen, and Capital Reserve amounted to 4,680,850 thousand yen.

The Company's common shares were listed on the Osaka Securities Exchange JASDAQ Growth Market on October 20, 2011. As a result of this IPO, outstanding shares increased to 5,100,000 and capital and capital reserves increased to 1,313,760 thousand yen on October 19, 2011.

(7) Important Subsequent Events

Important New Stock Issuance

The Company's common shares were listed on the Osaka Securities Exchange JASDAQ Growth Market on October 20, 2011. Payment was completed on October 19, 2011, after the approval of new stock issuances at Board of Directors meetings held on September 14 and 29, 2011.

As a result, capital increased to 6,024,610 thousand yen and outstanding shares increased to 19,130,900.

1. Offering

Public Offering with Book-Building Method

2. Type of Stocks to be issued

Common Shares 5,100,000

3. Issue Price

560 yen per share

4. Subscription Price

515.2 yen per share

This price was received from the underwriter as a payment for new issued shares. The difference between issue price and subscription price is the amount received by underwriters.

5. Amount to be Paid per Share (by Corporate Law)

391 yen per share

6. Included to Capital

257.6 yen per share

7. Total Amount of Issue Price

2,856,000 thousand yen

8. Total Amount of Subscription Price

2,627,520 thousand yen

9. Total Amount to be Paid (by Corporate Law)

1,994,100 thousand yen

10. Total Amount Included to Capital

1,313,760 thousand yen

11. Payment Due

October 19, 2011

12. Purpose of Cash Receipts

All amounts will be invested in phase 1 clinical trials and milestone payments for SyB L-1101, as well as phase 2 clinical trials and milestone payments for SyB L-0501 to develop the refractory and relapsed multiple myeloma, frontline low-grade NHL and MCL indications in 2012 and 2013. With this purpose in mind, the Company will follow a policy of investing funds in safer securities.